Product Description
DeTIL-0255 is an autologous cell therapy consisting of T cells derived from a patient’s tumor expanded ex vivo with NX-0255, a small molecule Casitas B lineage lymphoma-b (CBL-B) inhibitor developed by Nurix. DeTIL-0255 is a single administration autologous TIL therapy infused following non-myeloablative chemotherapy. Based on extensive preclinical characterization, Nurix believes DeTIL-0255 could allow a broader application of TIL therapy in a range of solid tumors. (Sourced from: https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-ind-clearance-detil-0255-drug#:~:text=DeTIL%2D0255%20is%20an%20autologous,infused%20following%20non%2Dmyeloablative%20chemotherapy.)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nurix Therapeutics
Company Location: SAN FRANCISCO CA 94158
Company CEO: Arthur T. Sands
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Mixed Tumor, Malignant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| None | P1 |
None |
Mixed Tumor, Malignant |
None |
None |